Compare Panacea Biotech with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs STRIDES PHARMA SCIENCE - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH STRIDES PHARMA SCIENCE PANACEA BIOTECH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 17.1 42.1 40.6% View Chart
P/BV x 6.7 2.0 338.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PANACEA BIOTECH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
PANACEA BIOTECH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3541,147 30.8%   
Low Rs138642 21.5%   
Sales per share (Unadj.) Rs74.6317.2 23.5%  
Earnings per share (Unadj.) Rs6.77.8 85.1%  
Cash flow per share (Unadj.) Rs15.525.1 61.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs57.2274.3 20.9%  
Shares outstanding (eoy) m61.2589.50 68.4%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x3.32.8 117.0%   
Avg P/E ratio x36.8114.0 32.3%  
P/CF ratio (eoy) x15.935.7 44.5%  
Price / Book Value ratio x4.33.3 131.8%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m15,06180,058 18.8%   
No. of employees `0002.32.5 92.3%   
Total wages/salary Rs m1,4714,341 33.9%   
Avg. sales/employee Rs Th1,973.611,325.8 17.4%   
Avg. wages/employee Rs Th635.61,731.4 36.7%   
Avg. net profit/employee Rs Th176.8280.1 63.1%   
INCOME DATA
Net Sales Rs m4,56728,394 16.1%  
Other income Rs m45941 4.8%   
Total revenues Rs m4,61229,334 15.7%   
Gross profit Rs m2,0303,965 51.2%  
Depreciation Rs m5401,540 35.1%   
Interest Rs m1,0481,962 53.4%   
Profit before tax Rs m4861,403 34.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m7797 79.2%   
Profit after tax Rs m409702 58.3%  
Gross profit margin %44.414.0 318.2%  
Effective tax rate %15.96.9 228.7%   
Net profit margin %9.02.5 362.3%  
BALANCE SHEET DATA
Current assets Rs m2,41524,836 9.7%   
Current liabilities Rs m9,07718,993 47.8%   
Net working cap to sales %-145.920.6 -709.0%  
Current ratio x0.31.3 20.3%  
Inventory Days Days6571 91.7%  
Debtors Days Days71113 62.5%  
Net fixed assets Rs m8,33334,289 24.3%   
Share capital Rs m61895 6.8%   
"Free" reserves Rs m3,44323,651 14.6%   
Net worth Rs m3,50424,546 14.3%   
Long term debt Rs m46115,513 3.0%   
Total assets Rs m13,75565,437 21.0%  
Interest coverage x1.51.7 85.4%   
Debt to equity ratio x0.10.6 20.8%  
Sales to assets ratio x0.30.4 76.5%   
Return on assets %10.64.1 260.2%  
Return on equity %11.72.9 408.2%  
Return on capital %38.76.9 561.3%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20315,697 7.7%   
Fx outflow Rs m467735 63.5%   
Net fx Rs m73614,962 4.9%   
CASH FLOW
From Operations Rs m1,0491,871 56.1%  
From Investments Rs m-545,826 -0.9%  
From Financial Activity Rs m-1,011-10,157 10.0%  
Net Cashflow Rs m-20-2,615 0.8%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 37.8 1.6%  
FIIs % 1.3 8.6 15.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 25.9 91.1%  
Shareholders   10,259 56,241 18.2%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  VENUS REMEDIES  WYETH  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 14, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS